|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 09, 2016 ) Rising incidence rate of dengue in tropical and subtropical regions has billed it one of the most critical vector-borne diseases in the world. The growing fear among humans about getting infected with Aedes mosquito (dengue vector) has encouraged the implementation of several preventive measures around the world. The global market for dengue vaccines is exhibiting drastic reforms as newer medical constituents are being researched and clinically-tested to develop effective vaccine candidates for curing dengue-affected patients.
Efforts are being made in terms of vector control and immunity drives, but the need to develop a completely harmless yet effective dengue vaccine is a major medical concern. While removal of stagnant water bodies, breeding of copepods or guppy fish (poecilia reticulata) in still waters and rehabilitation of human civilisations are recognised as the conventional trends for preventing dengue infections, it is important to address the most recent practices carried out to curb the impact of dengue across the globe.
A free sample of FMI’s report on dengue vaccines market is available for download at http://www.futuremarketinsights.com/reports/dengue-vaccines-market
Prominent Trends in Global Dengue Vaccine Market
The impending evaluation of several vaccine candidates has incited the additional expenditure in the clinical research on dengue vaccines. In several virology centres across the world, the developments in the clinical trials of new dengue vaccine candidates are being incorporated with the latest technological advancements. These centres are compiling such information and creating preclinical case studies that will prove beneficial for the evaluation tests and trials of vaccine candidates in the future.
The biopharmaceutical manufacturers participating in the production of clinically-approved dengue vaccines are being actively involved in the research process. Owing to this, several leading companies are investing capital in building up their own research facilities and gain dominance in the clinical trial procedures of new vaccine candidates. Even the candidates that do not perform extremely well in clinical trials are being further used to develop medicines that are less-effective yet affordable.
One of the most significant trend recognised in the global dengue vaccines market is the attempts of virology organisations in immunising the mosquitoes from being infected by the dengue virus at the very initial stages. The injection of Wolbachia genus bacteria has resulted higher resistance against the dengue virus in mosquitoes, and is expected to be used in clinical trials for developing liquids that can be sprayed on breeding grounds.
Complications arriving from the use of existing dengue vaccines will continue to influence the developments in the design of these vaccines. The antibody-deployment structure of these vaccines is getting remodelled in order to bring forth complex vaccine mechanism. Moreover, the exhaustive research on the viral protein in Aedes mosquitoes has also catalysed the development of highly-effective drugs.
The rising dengue-associated mortality rate has forced the hospitals in pressurising the respective governments to leverage the financial burden on the healthcare sector. The global pharmaceutical powerhouses are adapting to the lesser-profitable ways and lowering the costs of effective vaccines, which is fuelling the consumption levels.
The authors of FMI’s report on Dengue Vaccines Market can be reached at http://www.futuremarketinsights.com/askus/rep-gb-1760
Future Market Insights
Abhishek Budholiya
2076928790
abhishek.b@futuremarketinsights.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
